Aptevo Therapeutics Inc

NASDAQ:APVO  
23.61
-0.10 (-0.42%)
Twitter Share  Facebook Share StockTwits Share

Search For a Symbol

Market Cap (Intraday)104.57M
Current PEN/A
Forward PE N/A
2yr Forward PE N/A
See more stats
Estimates Current Quarter
Revenue$1.74 Million
Adjusted EPS-$1.51
See more estimates
10-Day MA$25.33
50-Day MA$29.13
200-Day MA$24.64
See more pivots

Aptevo Therapeutics Inc Stock, NASDAQ:APVO

2401 4th Avenue, Suite 1050, Seattle, Washington 98121
United States of America
Phone: +1.206.838.0500
Number of Employees: 58

Description

Aptevo Therapeutics, Inc. is a clinical-stage biotechnology company, which focuses on developing novel immunotherapies for the treatment of cancer. Its pipeline APVO436, ALG.APV-527 and APVO603 were developed based on the ADAPTIR modular protein platform technology and APVO442 was developed based on the new ADAPTIR-FLE platform technology. The ADAPTIR and ADAPTIR-FLEX are capable of generating differentiated bispecific and multi-specific antibodies with potentially unique mechanisms of action for the treatment of different types of cancer. The company was founded on February 22, 2016 and is headquartered in Seattle, WA.